Organon & Co. (NYSE:OGN) Upgraded at Barclays

Barclays upgraded shares of Organon & Co. (NYSE:OGN) to a strong sell rating in a research note published on Monday morning,Zacks.com reports.

A number of other brokerages also recently weighed in on OGN. Morgan Stanley cut their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. JPMorgan Chase & Co. cut their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Finally, Piper Sandler lowered shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, Organon & Co. presently has a consensus rating of “Reduce” and a consensus target price of $8.38.

Organon & Co. Stock Performance

NYSE OGN opened at $7.21 on Monday. The company has a fifty day moving average price of $8.07 and a 200-day moving average price of $9.19. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 3.75, a PEG ratio of 1.49 and a beta of 0.57. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. Organon & Co. has a 1 year low of $6.18 and a 1 year high of $17.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the firm earned $1.38 earnings per share. As a group, equities research analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Thursday, November 20th will be paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, November 20th. Organon & Co.’s dividend payout ratio is presently 4.17%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new position in shares of Organon & Co. during the 1st quarter valued at $8,773,000. Public Sector Pension Investment Board raised its stake in shares of Organon & Co. by 27.3% during the first quarter. Public Sector Pension Investment Board now owns 816,736 shares of the company’s stock worth $12,161,000 after acquiring an additional 175,092 shares in the last quarter. Kovitz Investment Group Partners LLC purchased a new position in Organon & Co. in the 1st quarter worth $333,000. KLCM Advisors Inc. lifted its stake in shares of Organon & Co. by 3.7% in the 1st quarter. KLCM Advisors Inc. now owns 1,273,599 shares of the company’s stock valued at $18,964,000 after acquiring an additional 45,950 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Organon & Co. during the 1st quarter valued at about $157,000. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.